VAIA
VKTX icon

Virtus Alternative Investment Advisers’s Viking Therapeutics VKTX Stock Holding History

Virtus Alternative Investment Advisers’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-843
Closed -$5K – 222
2020
Q4 		$5K Sell
843
-814
-49% -$4.93K 0.07% 268
2020
Q3 		$10K Sell
1,657
-864
-34% -$5.95K 0.18% 265
2020
Q2 		$18K Buy
+2,521
New +$16.7K 0.28% 76

Other funds holding VKTX

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Virtus Alternative Investment Advisers's VKTX Position: Q1 2021 in Review

Virtus Alternative Investment Advisers sold out of Viking Therapeutics (VKTX) in Q1 2021, closing a stake of 843 shares — an estimated $5K sold.

Virtus Alternative Investment Advisers first reported a position in VKTX in Q2 2020 and held it in 3 quarters. The position peaked at $18K in Q2 2020. 144 funds tracked by Wall St. Rank hold VKTX as of Q1 2021.

  • Virtus Alternative Investment Advisers reported no remaining Viking Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Virtus Alternative Investment Advisers sold 843 Viking Therapeutics shares in Q1 2021, an estimated $5K.
  • Virtus Alternative Investment Advisers first reported a position in Viking Therapeutics in Q2 2020 and held it in 3 quarters.
  • Virtus Alternative Investment Advisers's Viking Therapeutics position peaked at $18K in Q2 2020.
  • 144 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2021.

Based on Virtus Alternative Investment Advisers's 13F filing for Q1 2021.